Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 11/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 11/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.41 |
| ▸ | CDK2 | P24941 | 6/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 3/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5347574 | 0.84 | CDK5 (0.65) | CDK5CDK5R1ROCK1DYRK1ACCNA2 | |
| SCHEMBL5342987 | 0.84 | CDK5 (0.57) | CDK5CDK5R1ROCK1DYRK1ACCNA2 | |
| SCHEMBL5342153 | 0.84 | CDK5 (0.57) | CDK5CDK5R1ROCK1DYRK1ACCNA2 | |
| SCHEMBL5341602 | 0.81 | CDK5 (0.54) | CDK5CDK5R1ROCK1DYRK1ACCNA2 | |
| SCHEMBL5342474 | 0.80 | CDK5 (0.53) | CDK5CDK5R1ROCK1DYRK1ACCNA2 | |
| SCHEMBL5339059 | 0.80 | CDK5 (0.51) | CDK5CDK5R1ROCK1DYRK1ACCNA2 | |
| SCHEMBL5345974 | 0.79 | CDK5 (0.54) | CDK5CDK5R1ROCK1DYRK1ACCNA2 | |
| SCHEMBL14558890 | 0.79 | CDK5 (0.53) | CDK5CDK5R1ROCK1DYRK1ACCNA2 | |
| SCHEMBL6630007 | 0.78 | CDK5 (0.53) | CDK5CDK5R1ROCK1DYRK1ACCNA2 | |
| SCHEMBL14558866 | 0.76 | CDK5 (0.53) | CDK5CDK5R1ROCK1DYRK1ACCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1309589-B1 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1619184-A2 | Urea compounds as kinase inhibitors | Amgen, Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1483263-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| WO-2003070727-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-1309589-A2 | UREA COMPOUNDS AND METHODS OF USES | Amgen Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020173507-A1 | Urea compounds and methods of uses | AMGEN INC. | 2002-11-21 | — | — | US | disclosed |
| WO-2002014311-A2 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | CDK5 64/4885CDK5R1 359/4885ROCK1 3731/4885 |
| US-20020173507-A1 | Urea compounds and methods of uses | SLC14A1, UMPS, BAX | CDK5 40/4885CDK5R1 244/4885ROCK1 3616/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | CDK5 64/4885CDK5R1 359/4885ROCK1 3731/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | CDK5 64/4885CDK5R1 359/4885ROCK1 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.